A Look At The Proposed EU IP Exception To Promote Generic, Biosimilar Industry Competitiveness 16/11/2018 by David Branigan, Intellectual Property Watch 1 Comment The European Commission has proposed an exception to the extended period of patent protection that the European Union provides to original drug manufacturers for certain products, in order to boost the competitiveness of EU generic and biosimilar industries in global markets. The exception will allow EU generic and biosimilar companies to manufacture protected drugs for export during this patent extension period. Stakeholders are so far unhappy with the exception. Meanwhile, studies analyse its potential economic impacts and legal implications, and the Commission remains confident that safeguards it is putting in place will keep the lower-priced medicines from making their way back into the EU.
Global Biotech Industry Revisits Geneva, Seeks To Build Relationships To Help Shape Policies 14/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment A global association representing biotechnology industries last week made a second annual visit to Geneva’s institutions to raise awareness of how the industry works, its needs, and how the association could participate better in policymaking. Dismissing fears of industry unduly influencing public policies, two representatives of the association sat down with Intellectual Property Watch’s Catherine Saez to explain the importance of biotechnology in solving the problems of the world, and the need to raise awareness of the perspective of the biotechnology sector.
IP Experts Discuss US Congressional Changes, Prospects For IP Legislation 13/11/2018 by William New, Intellectual Property Watch 1 Comment NEW YORK – Major changes are coming to the makeup of the US Congress from the perspective of intellectual property policy, and while it may translate into more patent-friendly officials, the prospect for legislation is uneven, a panel of IP experts told a private sector conference here last week.
Experts Assess Coming Changes In US Courts And Patentability 09/11/2018 by William New, Intellectual Property Watch 2 Comments NEW YORK — A panel of legal and government experts this week discussed trends in courts in the United States on patent cases and changes underway at the US Patent and Trademark Office. One conclusion? There may be a real shift in what is seen as patentable in the US, but it may take an act of Congress. [Note: part 1 of 2. The second part will address this week’s changes in the US Congress.]
Report Finds “Overpatenting”, Overpricing Of Top Diabetes Drug In US 05/11/2018 by David Branigan, Intellectual Property Watch 1 Comment Non-profit patent researchers studying the most prominent prescription insulin drug to treat diabetes in the United States found it is “overpatented” and “overpriced,” enabling unwarranted price-hikes resulting in rising costs for patients and taxpayers.
USPTO Solicitor/Deputy General Counsel Leaves For DC Law Firm 05/11/2018 by Intellectual Property Watch Leave a Comment Nathan Kelley has stepped down from his role as solicitor and deputy general counsel at the United States Patent and Trademark Office (USPTO) to join the Perkins Coie law firm in Washington, DC. Kelley also had served as chief administrative patent judge in charge of the Patent Trial and Appeal Board (PTAB).
Group Proposes Regulating Internet Hate Speech Through Decentralisation 01/11/2018 by David Branigan, Intellectual Property Watch Leave a Comment French advocacy group La Quadrature du Net has declared recent French government plans to regulate internet hate speech insufficient, and is calling for more in-depth reforms. These could include the promotion of alternative social media platforms and a decentralised approach to regulation, according to an organisation press release.
Advocates Call For New US Federal Authority On Artificial Intelligence 31/10/2018 by Intellectual Property Watch Leave a Comment Public Knowledge, a Washington, DC advocacy group, today released a paper calling for the formation of a new federal government authority to develop expertise and capacity on artificial intelligence (AI), to be able to effectively regulate and govern these technologies in the future.
Report: Is China Gaining The Inside Track On Standards For “Internet Of Things” Technology? 31/10/2018 by David Branigan, Intellectual Property Watch Leave a Comment A new US private sector report asserts that China is gaining the inside track on international standard-setting for “Internet of Things” technology, and offers strategies for the United States to keep competitive in the marketplace by maintaining influence over standard-setting while protecting data security.
New Report: Mitigating Patent Linkage To Promote Medicines Access In LMICs 26/10/2018 by David Branigan, Intellectual Property Watch 1 Comment A new report reviews how patent linkage mechanisms have been implemented in South Korea, Australia, Canada, and the United States, and identifies precedents for how low and middle-income countries (LMICs) can retain and exploit “constructive ambiguities” in trade treaty text to mitigate the impacts of patent linkage mechanisms and promote the timely availability of generic medicines.